Connection

Mark Rubinstein to Mice

This is a "connection" page, showing publications Mark Rubinstein has written about Mice.
Connection Strength

0.817
  1. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
    View in: PubMed
    Score: 0.067
  2. Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. Cancer Immunol Immunother. 2017 Jun; 66(6):737-751.
    View in: PubMed
    Score: 0.062
  3. IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
    View in: PubMed
    Score: 0.056
  4. Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Ra Dependent. Cancer Immunol Res. 2015 Dec; 3(12):1364-74.
    View in: PubMed
    Score: 0.055
  5. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother. 2015 May; 64(5):539-49.
    View in: PubMed
    Score: 0.053
  6. G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol. 2013 Oct 01; 6:75.
    View in: PubMed
    Score: 0.049
  7. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012 Apr; 214(4):700-7; discussion 707-8.
    View in: PubMed
    Score: 0.044
  8. IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response. Blood. 2008 Nov 01; 112(9):3704-12.
    View in: PubMed
    Score: 0.034
  9. Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo. Cancer Gene Ther. 2009 Feb; 16(2):171-83.
    View in: PubMed
    Score: 0.034
  10. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9166-71.
    View in: PubMed
    Score: 0.029
  11. Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol. 2003 Feb 01; 170(3):1209-17.
    View in: PubMed
    Score: 0.023
  12. Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model. PLoS One. 2022; 17(9):e0273076.
    View in: PubMed
    Score: 0.023
  13. B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022 01; 10(1).
    View in: PubMed
    Score: 0.022
  14. Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. Oncoimmunology. 2021; 10(1):1959101.
    View in: PubMed
    Score: 0.021
  15. Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells. Eur J Immunol. 2020 09; 50(9):1386-1399.
    View in: PubMed
    Score: 0.019
  16. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Ra Complexes Enhances Tumor Control. Cancer Immunol Res. 2019 08; 7(8):1371-1380.
    View in: PubMed
    Score: 0.018
  17. Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells. J Biol Chem. 2019 06 07; 294(23):9198-9212.
    View in: PubMed
    Score: 0.018
  18. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses. J Biol Chem. 2016 Nov 11; 291(46):23869-23881.
    View in: PubMed
    Score: 0.015
  19. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. Cancer Immunol Res. 2016 09 02; 4(9):799-811.
    View in: PubMed
    Score: 0.015
  20. Lack of p53 Augments Antitumor Functions in Cytolytic T Cells. Cancer Res. 2016 09 15; 76(18):5229-5240.
    View in: PubMed
    Score: 0.015
  21. Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. J Immunotoxicol. 2016 11; 13(6):784-792.
    View in: PubMed
    Score: 0.015
  22. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clin Cancer Res. 2015 Jun 01; 21(11):2546-57.
    View in: PubMed
    Score: 0.014
  23. The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015 Feb 15; 194(4):1737-47.
    View in: PubMed
    Score: 0.013
  24. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor aSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15; 73(10):3075-86.
    View in: PubMed
    Score: 0.012
  25. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc Natl Acad Sci U S A. 2010 Dec 14; 107(50):21647-52.
    View in: PubMed
    Score: 0.010
  26. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010 Oct 01; 70(19):7465-75.
    View in: PubMed
    Score: 0.010
  27. The lymphopenic environment of CD132 (common gamma-chain)-deficient hosts elicits rapid homeostatic proliferation of naive T cells via IL-15. J Immunol. 2008 Apr 15; 180(8):5320-6.
    View in: PubMed
    Score: 0.008
  28. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 2008 Apr 15; 68(8):2972-83.
    View in: PubMed
    Score: 0.008
  29. An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. J Exp Med. 2007 Aug 06; 204(8):1787-801.
    View in: PubMed
    Score: 0.008
  30. Antiviral CD4+ memory T cells are IL-15 dependent. J Exp Med. 2007 Apr 16; 204(4):951-61.
    View in: PubMed
    Score: 0.008
  31. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007 Jan; 30(1):40-53.
    View in: PubMed
    Score: 0.008
  32. Simultaneous deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch allograft rejection. Eur J Immunol. 2006 Aug; 36(8):1994-2002.
    View in: PubMed
    Score: 0.007
  33. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006 Mar 31; 311(5769):1924-7.
    View in: PubMed
    Score: 0.007
  34. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol. 2004 May 01; 172(9):5159-67.
    View in: PubMed
    Score: 0.006
  35. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
    View in: PubMed
    Score: 0.006
  36. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol. 2003 Mar 01; 170(5):2582-9.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.